The combination of Kedrion and BPL creates a global player for medicinal products derived from human blood plasma, which treat patients with rare and life-threatening conditions. Headquartered in Italy, the business has a US plasma collection footprint of 75 centres with a portfolio of 37 life-saving products. The company combines two leading pharmaceutical companies: Kedrion Biopharma, a leading Italian plasma derivates player with an extensive portfolio of 21 products, and Bio Products Laboratory (BPL), one of the fastest growing players in the plasma industry over the past five years, based in the UK.